Achondroplasia Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Sanofi, Changchun GeneScience Pharma, QED Therapeutics, Inc., BridgeBio, QED Therapeutics , Ribomic

The Key Achondroplasia Companies in the market include - BridgeBio/ QED Therapeutics , Ribomic Inc, Sanofi, Changchun GeneScience Pharma, Ascendis Pharma A/S, QED Therapeutics, Inc, BioMarin Pharmaceuticals, BioMarin Pharmaceutical, and others.

DelveInsight's "Achondroplasia Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Achondroplasia, historical and forecasted epidemiology as well as the Achondroplasia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Achondroplasia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Achondroplasia Market Forecast [https://www.delveinsight.com/sample-request/achondroplasia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Achondroplasia Market Report:

*
The Achondroplasia market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

*
In November 2024, RIBOMIC, Inc. (TOKYO:4591), a clinical-stage pharmaceutical company focused on aptamer therapeutics, has been conducting a Phase IIa clinical trial of umedaptanib pegol (anti-FGF2 aptamer) in pediatric patients (ages 5-14) with achondroplasia (ACH). The company announced today that the low-dose (0.3 mg/kg) subcutaneous injection group (cohort 1), administered once a week, has completed treatment, showing a positive effect on the growth rate of the patients.

*
In September 2024, BridgeBio Pharma, Inc. (Nasdaq: BBIO), a biopharmaceutical company specializing in genetic diseases, today announced that the FDA has granted Breakthrough Therapy Designation to oral infigratinib, which is being developed for the treatment of children with achondroplasia.

*
In Febraury 2024, Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company dedicated to developing next-generation precision medicines targeting Fibroblast Growth Factor Receptor (FGFR) biology, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) Designation to TYRA-300, an oral FGFR3 selective inhibitor, for the treatment of achondroplasia.

*
In the United States, achondroplasia impacts a slightly higher percentage of females (51.2%) compared to males (48.8%). This slight difference may be attributed to genetic or biological factors that contribute to its somewhat greater prevalence in females.

*
In 2023, the total number of diagnosed prevalent cases of achondroplasia in Japan and the US was approximately 18,000, with expectations for this number to increase in the coming years.

*
In 2023, Japan had around 3,000 diagnosed prevalent cases of achondroplasia.

*
The epidemiology model categorizes age-specific cases into nine groups: 0-4, 5-10, 11-15, 16-20, 21-30, 31-40, 41-50, 51-60, and over 60. DelveInsight's estimates indicate that the 5-10 age group was the most affected in the US, with around 4,000 cases reported in 2023.

*
Achondroplasia is estimated to occur in 1 out of every 15,000 to 40,000 live births, making it one of the most prevalent types of skeletal dysplasia.

*
Key Achondroplasia Companies: BridgeBio/ QED Therapeutics , Ribomic Inc, Sanofi, Changchun GeneScience Pharma, Ascendis Pharma A/S, QED Therapeutics, Inc, BioMarin Pharmaceuticals, BioMarin Pharmaceutical, and others

*
Key Achondroplasia Therapies: VOXZOGO (vosoritide), Infigratinib, RBM-007, SAR-442501, Recombinant human growth hormone, Infigratinib, TransCon CNP, Infigratinib, vosoritide, BMN 111, and others

*
The Achondroplasia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Achondroplasia pipeline products will significantly revolutionize the Achondroplasia market dynamics.

Achondroplasia Overview

Achondroplasia is a genetic disorder that causes abnormal bone growth, resulting in short stature and disproportionate limb size. It is the most common form of dwarfism, typically characterized by a larger head, short arms and legs, and a normal-sized trunk. The condition is caused by mutations in the FGFR3 gene, which affects the development of cartilage into bone. Individuals with achondroplasia may also experience other health issues such as joint problems, spinal abnormalities, and ear infections. Treatment focuses on managing symptoms, and while there is no cure, growth hormone therapy and other treatments can help improve quality of life.

Get a Free sample for the Achondroplasia Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/achondroplasia-market [https://www.delveinsight.com/report-store/achondroplasia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Achondroplasia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Achondroplasia Epidemiology Segmentation:

The Achondroplasia market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of Achondroplasia

*
Prevalent Cases of Achondroplasia by severity

*
Gender-specific Prevalence of Achondroplasia

*
Diagnosed Cases of Episodic and Chronic Achondroplasia

Download the report to understand which factors are driving Achondroplasia epidemiology trends @ Achondroplasia Epidemiology Forecast [https://www.delveinsight.com/sample-request/achondroplasia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Achondroplasia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Achondroplasia market or expected to get launched during the study period. The analysis covers Achondroplasia market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Achondroplasia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Achondroplasia Therapies and Key Companies

*
VOXZOGO (vosoritide): BioMarin Pharmaceuticals

*
Infigratinib: BridgeBio/ QED Therapeutics

*
RBM-007: Ribomic Inc

*
Recombinant human growth hormone: Changchun GeneScience Pharma

*
Infigratinib: QED Therapeutics, Inc.

*
TransCon CNP: Ascendis Pharma A/S

*
Infigratinib: QED Therapeutics, Inc

*
vosoritide: BioMarin Pharmaceuticals

*
BMN 111: BioMarin Pharmaceutical

Scope of the Achondroplasia Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Achondroplasia Companies: BridgeBio/ QED Therapeutics , Ribomic Inc, Sanofi, Changchun GeneScience Pharma, QED Therapeutics, Inc., Ascendis Pharma A/S, QED Therapeutics, Inc, BioMarin Pharmaceuticals, BioMarin Pharmaceutical, and others

*
Key Achondroplasia Therapies: VOXZOGO (vosoritide), Infigratinib, RBM-007, SAR-442501, Recombinant human growth hormone, Infigratinib, TransCon CNP, Infigratinib, vosoritide, BMN 111, and others

*
Achondroplasia Therapeutic Assessment: Achondroplasia current marketed and Achondroplasia emerging therapies

*
Achondroplasia Market Dynamics: Achondroplasia market drivers and Achondroplasia market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Achondroplasia Unmet Needs, KOL's views, Analyst's views, Achondroplasia Market Access and Reimbursement

To know more about Achondroplasia companies working in the treatment market, visit @ Achondroplasia Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/achondroplasia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Achondroplasia Market Report Introduction

2. Executive Summary for Achondroplasia

3. SWOT analysis of Achondroplasia

4. Achondroplasia Patient Share (%) Overview at a Glance

5. Achondroplasia Market Overview at a Glance

6. Achondroplasia Disease Background and Overview

7. Achondroplasia Epidemiology and Patient Population

8. Country-Specific Patient Population of Achondroplasia

9. Achondroplasia Current Treatment and Medical Practices

10. Achondroplasia Unmet Needs

11. Achondroplasia Emerging Therapies

12. Achondroplasia Market Outlook

13. Country-Wise Achondroplasia Market Analysis (2020-2034)

14. Achondroplasia Market Access and Reimbursement of Therapies

15. Achondroplasia Market Drivers

16. Achondroplasia Market Barriers

17. Achondroplasia Appendix

18. Achondroplasia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=achondroplasia-market-to-show-remarkable-growth-trends-from-2024-to-2034-delveinsight-reports-sanofi-changchun-genescience-pharma-qed-therapeutics-inc-bridgebio-qed-therapeutics-ribomic]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.